Patients must have histologically or cytologically confirmed alveolar soft part sarcoma that is not curable by surgery; diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollment
Histologically- or cytologically-confirmed CRC that is metastatic
Histologically or cytologically confirmed cholangiocarcinoma.
Patients must have a biopsy with histologically confirmed diagnosis of recurrent endometrial cancer confined to the pelvis and/or vagina and no evidence of extrapelvic disease
Histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ? 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in >50% of tumor cells.
Patients must have histologically or cytologically confirmed non-rhabdomyosarcoma of soft tissue or bone at any site
Histologically confirmed advanced malignant melanoma, regardless of subtype (for screening and treatment phases)
Have histologically or cytologically confirmed SCLC that meets:
Phase 1: Subjects must have a histologically or cytologically confirmed diagnosis of metastatic (AJCC stage IV) NSCLC that carries an ALK rearrangement with CNS metastases, as determined by FISH, RT-PCR, immunohistochemistry (IHC), or NGS via a CLIA-certified LDT
Have a histologically-confirmed diagnosis of MB, NB, ES, or ARMS
Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment
Patients must have persistent or recurrent histologically confirmed USC
The diagnosis must be histologically confirmed by a gynecologic pathologist as containing >= 10% uterine papillary serous (UPSC) adenocarcinoma in the specimen
Part 1: A confirmed diagnosis of FL Grade 1, 2, or 3a, which has relapsed after, or been refractory to ? 1 prior therapy for FL, or subjects who have not previously received systemic anticancer therapy for FL., and which requires treatment. Part 2:Histologically confirmed MZL including splenic, nodal, and extranodal sub- types
Histologically confirmed metastatic or recurrent Type II EC (serous, clear cell, carcinosarcoma, adenosquamous and mixed histologies).
Epithelial Endometrial Cancer: histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of recurrent previously treated EEC.
Histologically or cytologically confirmed limited or extensive disease stage of SCLC. The disease should be progressing during or relapsing after the previous treatment.
Patients must have cytologically or histologically confirmed relapsed or refractory extensive-disease small-cell lung cancer (ES-SCLC) or non-progressing ES-SCLC after first line chemotherapy, or advanced or inoperable grade I-II pulmonary NETs
New diagnosis of brain metastases from a histologically or cytologically confirmed primary or metastatic NSCLC tumor within 5 years of registration on the study. If the original histological proof of malignancy is greater than 5 years, then pathological confirmation is required (i.e.: from extra-cranial or intracranial disease).
Histologically or cytologically confirmed metastatic UM
Histologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that is relapsed and/or refractory.
Histologically or cytologically confirmed AML according to the WHO classification
Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
Part 2: HNSCC, with confirmed p53 mutations
(Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have not received prior systemic anticancer therapy for advanced or metastatic disease.
Participants must have histologically confirmed malignant tumor
Histologically confirmed CAH or grade 1 EC
Part B5 only: Participants must have histologically confirmed diagnosis of B-cell iNHL, with histological subtype; prior treatment with ?2 prior chemotherapy- or immunotherapy-based regimens for iNHL
Histologically confirmed neurotropic primary melanoma
Patients must have must have histologically or cytologically confirmed SCLC
Histologically confirmed classical HCL by the enrolling institution
Histologically or cytologically confirmed BRAFV600 wild-type melanoma
Prior diagnosis of Langerhans cell histiocytosis (strata A and B) or LCH-related disorder (stratum C) established by standard diagnostic criteria and confirmed histologically
Histologically or cytologically confirmed ovarian epithelial cancer
Have histologically or cytologically confirmed diagnosis of SCCHN irrespective of PD-L1 status, which is either inoperable and recurrent, or metastatic
Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, Hurthle cell or poorly differentiated subtypes and their respective variants)
Histologically confirmed advanced TET (thymoma or thymic carcinoma)
Patients must have histologically or cytologically confirmed non-mucinous, epithelial stage 3 or 4 carcinoma of the ovary, fallopian tube or peritoneum
Patients must have histologically or cytologically confirmed metastatic/recurrent adenoid cystic carcinoma (ACC) or non-adenoid cystic carcinomas (non-ACC) of major or minor salivary glands
Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification
Histologically confirmed malignancy of the bladder
Histologically- or cytologically- confirmed CRC
Must have a histologically or cytologically confirmed, incurable malignancy, for which further standard treatment is not currently available.
Histologically confirmed FL.
Histologically or cytologically confirmed hematologic malignancy
Patients must have histologically or cytologically confirmed epithelial endometrial carcinoma; all histologies are accepted; patients with diagnosis of endometrial carcinosarcoma will be enrolled in the exploratory cohort (arm C) and will receive combination of cabozantinib and nivolumab
Subjects with histologically or cytologically confirmed extensive stage disease SCLC
Phase I portion of the study: Patients with histologically confirmed classical hairy cell leukemia (HCL)
Histologically or cytologically confirmed malignant secretory or non-secretory pheochromocytoma or paraganglioma that is unresectable and deemed inappropriate for alternative local regional therapeutic approaches
Patients must have histologically confirmed diagnosis of chordoma; the pathologic confirmation may be from another metastatic site
Patients with histologically or cytologically confirmed, resectable colon cancer and other resectable cancers without distant metastases, who are candidates for surgical resection of the tumor
Patients must be diagnosed with relapse of previously histologically confirmed PFEPN
Diagnosis of histologically or cytologically confirmed metastatic or non-resectable synovial sarcoma
Have histologically- or cytologically- confirmed unresectable or metastatic ACC that is considered incurable by local therapies
Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation
Histologically confirmed diagnosis of CD20 positive iNHL with histological subtype limited to:
CAPMATINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
REGORAFENIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
ENTRECTINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
Patients must have histologically confirmed diagnosis of osteosarcoma or Ewing sarcoma by central review, except if the diagnosis was already confirmed by the RRePS (Réseau de Référence en Pathologie des Sarcomes et des Tissus Mous et des Viscères) network
Histologically confirmed metastatic or recurrent HER2-negative (via IHC or FISH per ASCO/CAP guidelines 2013) breast cancer or histologically confirmed metastatic solid tumor
Histologically confirmed cancer by a Mount Sinai pathologist
Histologically- or cytologically-confirmed CRC
Patients with histologically or cytologically confirmed metastatic clear cell RCC who are eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy; diagnosis must be confirmed by pathologist review of screening biopsy; the determination of resectability will ultimately lie in the clinical judgment of the urologist and medical oncologist involved in the care of the patient
Patients must have pathologically confirmed GIST
Patients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows:
Participants must have histologically confirmed primary cancer of the uterus or cervix with histologically confirmed metastasis to one or more parametrial, pelvic, or para-aortic nodes prior to enrollment; participants diagnosed at other institutions must have pathology reviewed and confirmed at Massachusetts General Hospital (MGH) or another Dana-Farber (DF)/Harvard Cancer Center (HCC) institution
Patient must have suspected intrahepatic or hilar cholangiocarcinoma with minimal extrahepatic disease; diagnosis must be histologically or cytologically confirmed for continued treatment on study after pump placement
Patients must have histologically confirmed malignancy with brain metastases and are being recommended palliative WBRT
Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)
Histologically or cytologically confirmed (patients with mixed histologies are required to have a dominant transitional cell pattern.)
Histologically or cytologically confirmed metastatic or recurrent tumor types
Histologically or cytologically confirmed malignancy or lymphoproliferative disorder known to over express CK2 which has failed standard therapies (surgery, radiotherapy, endocrine therapy, chemotherapy) or for which effective therapy is not available, including the following types: (examples)
Histologically confirmed diagnosis of ACC according to Weiss system by a national reference pathologist who has to be nominated before study initiation.
Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies.
Histologically-confirmed T1b, T2 or T3 gallbladder cancer discovered incidentally at the time of or following routine cholecystectomy for presumed benign disease
Patients with histologically-confirmed Tis, T1a, or T4 tumors
Histologically- or cytologically-confirmed mCRC.
Women with biopsy confirmed high grade cervical intraepithelial lesions (diagnosis confirmed by\r\npositive p16 immunohistochemistry staining) within 12 weeks of baseline visit
Histologically-confirmed metastatic CRC
Histologically confirmed plasmacytoma amenable for biopsy
Patients must have histologically or cytologically confirmed metastatic endometrial cancer; eligible histologies for the experimental cohort are: endometrioid or serous; eligible histologies for the exploratory cohort are: carcinosarcoma, clear cell, mixed, adenosquamous and any other rare sub-type of endometrial cancer
Patients with histologically or cytologically confirmed metastatic NETs of any origin of low or intermediate grade (Part 1)
Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/ cholangiocarcinoma (including primary intra- and extrahepatic diseases); pathologic confirmation may be made from the primary or a metastatic site
Patients without histologically or cytologically confirmed node metastases or any other metastases
Study participants must have histologically or cytologically confirmed unresectable or metastatic malignant melanoma
Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary appendiceal tumors
Patients with chemotherapy (chemo)-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic subclassification
The diagnosis must be histologically confirmed by a gynecologic pathologist as containing >= 10% UPSC adenocarcinoma in the specimen
Age ? 18 years with histologically confirmed diagnosis of melanoma and stage IIIB to IVM1c for whom surgery is not recommended.
Has one of the following histologically confirmed tumors:
Part 2: histologically confirmed disease in specific tumor types
Subjects with histologically or cytologically confirmed NSCLC, MEL (including I/O relapsed MEL or I/O refractory MEL), CRC, SCCHN, ovarian cancer, recurrent B cell NHL or HL, or glioblastoma
Histologically or cytologically confirmed transitional cell carcinoma of the genitourinary tract
Have histologically or cytologically confirmed melanoma
Pathologically confirmed HER2-positive MBC
Patients with histologically confirmed intrahepatic, perihilar or extra-hepatic CCA.
has HER2 positive expression confirmed per protocol
Histologically or cytologically confirmed melanoma.
Based on RECIST v1.1 criteria on current nivolumab treatment (prior to initiation of this study), has a best response of confirmed stable disease (SD) or confirmed progressive disease (PD). Confirmed SD or confirmed PD refers to a response that is confirmed by a 2nd scan which is at least 4 weeks apart from the previous scan.
Histologically confirmed non-keratinizing differentiated NPC or undifferentiated NPC
Patients must have histologically-confirmed stage IV TNBC (patients who had metastatic disease within 6 months of lumpectomy or mastectomy for treatment of TNBC may be excused from repeat biopsy)
Specific eligibility criteria for Part 2 CRPC expansion cohort: Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuously medically castrated (for >=8 weeks prior to pre-screening).
Patients must have histologically or cytologically confirmed metastatic, high grade NET (Ki67 > 20%), excluding any high grade NETs of large or small cell type of lung/thymus origin and Merkel cell carcinoma
Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)
Histologically or cytologically confirmed advanced fibrolamellar carcinoma (FLC).
Inclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Patients with metastatic or advanced solid tumors\n\n          -  Women with histologically or cytologically confirmed triple negative breast carcinoma\n\n          -  Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n\n          -  Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer\n             (NSCLC)\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases.\n\n          -  Any serious or uncontrolled medical disorder\n\n          -  Prior malignancy active within the previous 3 years\n\n        Other protocol defined inclusion/exclusion criteria could apply
Histologically confirmed diagnosis of R/R AITL (eligibility needs to be confirmed by central pathological review).
Pathologically confirmed MCL.
Have a histologically or cytologically confirmed diagnosis of non-resectable, recurrent, or metastatic biliary tract adenocarcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or Ampulla of Vater) .
A histologically or cytologically confirmed cancer that is metastatic, unresectable, or recurrent and for which treatment with ipilimumab, or nivolumab, or pembrolizumab is a reasonable therapeutic option in the opinion of the investigator.
Patients must have pathologically confirmed GIST
Participants must have histologically confirmed B-cell NHL
Patients must have histologically or cytologically confirmed evidence of pancreatic carcinoma
Histologically confirmed melanoma of cutaneous origin
Confirmed or suspected endocarditis
Confirmed HER2 positive status
Patients must have pathologically confirmed GIST
Patients must have histologically-confirmed endometrial carcinoma (endometrioid and mixed endometrioid tumors, any grade).
Histologically or cytologically confirmed metastatic PDAC, no more than 1 prior chemotherapy regimen or treatment-naïve patients
Histologically- or cytologically- confirmed CRC
Patients must have histologically or cytologically confirmed gastrointestinal (GI) malignancies or ovarian cancer prior to entering this study
Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:
Histologically confirmed recurrent or metastatic SCCHN
Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants)
Histologically or cytologically confirmed diagnosis of pancreatic carcinoma (dose escalation and MTD expansion components).
Histologically confirmed papillary serous adenocarcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required);
Participants must have histologically or cytologically confirmed cervical cancer which is now recurrent or metastatic and is refractory to curative therapy or established treatments; histologic or cytologic confirmation of the original primary tumor is required; all histologic types of cervical origin are permitted
Pathologically or cytologically confirmed esophagogastric cancer
Histologically confirmed squamous cell carcinoma of the cervix (any grade) or histologically confirmed grade 1 or 2 adenocarcinoma of cervix
Histologically confirmed AML with >20% blasts
Histologically confirmed intrahepatic cholangiocarcinoma (also variously reported as peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma) (ICC); confirmation of the diagnosis must be made at MSKCC or at the participating institution prior to initiating protocol therapy
Patients must have histologically-confirmed advanced or recurrent endometrial carcinoma (endometrioid and mixed tumors, any grade) that is refractory to curative therapy or established treatments
Histologically confirmed diagnosis of mycosis fungoides (MF) or Sezary Syndrome (SS)
Histologically confirmed AL or LCDD (from any time prior to screening)
histologically-confirmed diagnosis according to REAL/WHO classification, of the following B-cell lymphomas :
Patients must have histologically or cytologically confirmed renal cell carcinoma except medullary or collecting duct subtypes; sarcomatoid differentiation will be allowed
Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:
Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation
Subjects must have histologically-confirmed chordoma
Patients’ biopsies must be histologically confirmed CD30 positive within 36 months of enrollment
Histologically-confirmed HL
Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:
Histologically confirmed MCL
Patients must have histologically or cytologically confirmed cancer
Histologically confirmed CD20 positive primary B-cell CNS lymphoma (PCNSL) confirmed by one of the following:
Patients must be males with histologically confirmed and clinically localized low-grade and low-volume prostate cancer demonstrated at the time of initial diagnosis
Patient has histologically/cytologically-confirmed HNSCC.
Patients with histologically confirmed viral related hepatocellular, SCLC, non-cutaneous/ non-uveal melanoma, ovarian, TNBC, Sarcoma, Bladder and RCC.
Histologically confirmed diagnosis of osteosarcoma with lung metastasis, who have progressed on the prior line of therapy, or relapsed
Patients with histologically/cytologically-confirmed HNSCC
Histologically confirmed non-squamous histologies are not allowed; an exception is made for WHO type I-III nasopharynx histologies
Histologically confirmed uterine leiomyosarcoma with disease limited to the uterus (determined by surgical staging or radiologic imaging).
Histologically or cytologically confirmed disease;
Patient with histologically/cytologically confirmed Primary Central Nervous System Lymphoma (PCNSL)
Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:
Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants).
Subjects with a histologically or cytologically confirmed acute leukemia who are refractory to or have exhausted all available therapies
Histologically documented leiomyosarcoma
Participants must have histologically confirmed intrahepatic cholangiocarcinoma (IHC) without evidence of extrahepatic metastasis within 3 months prior to study registration
Subjects with histologically or cytologically confirmed mCRC, Kirsten rat sarcoma wild-type (KRAS WT) at initial diagnosis
Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.
Histologically confirmed endometrial cancer
Histologically confirmed HCC that is inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons), and not eligible for local therapy
DOSE EXPANSION COHORT: subjects must have histologically or cytologically confirmed GIST that is metastatic or unresectable
Histologically or cytologically confirmed melanoma
Histologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anus
Histologically confirmed angiosarcoma
Patients must have histologically confirmed metastatic alveolar soft part sarcoma that is not curable by surgery; diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollment
Histologically- or cytologically-confirmed MPeM; epithelial, sarcomatoid, biphasic, multi-cystic, or well-differentiated papillary subtypes are allowed
SCLC pathologically confirmed at MSKCC
Histologically or cytologically confirmed salivary gland carcinoma.
Histologically confirmed medulloblastoma located in the posterior fossa            \r\n* Standard-risk disease
Patients must have histologically confirmed diagnosis of recurrent, persistent or advanced (stage IVB) squamous, adenocarcinoma or adenosquamous cervical cancer
Patients must have histologically or cytologically confirmed malignant melanoma and clinical evidence of metastatic disease to the brain; mucosal and ocular melanomas are included
Have histologically confirmed organ-confined prostate cancer - Clinical Stage T1 or T2a,
Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage
Pathologically confirmed NHL
Adolescents and young adults (AYA) with histologically confirmed cancer who have completed primary treatment
Patients must have histologically confirmed T3-T4 and N0-N2, M0 adenocarcinoma of the rectum with the inferior margin within 16 cm from the anal verge
Adult men of all races and body size with histologically confirmed localized PCa on AS
CANCER PATIENT GROUP: Histologically confirmed non-metastatic PCa
Adult patients > 18 years with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL)
Histologically-confirmed high grade dysplasia (HGD), cancer, or polyp burden that is not quantifiable
Naïve or non-naïve patient with histologically, and/or cytologically (or imaging in the case of brain tumors) confirmed malignant disease.
Histologically-confirmed chronic multifocal atrophic gastritis (MAG) and/or gastric intestinal metaplasia (GIM)
Age >= 18 years, with histologically confirmed diagnosis of Barrett's Esophagus without dysplasia
Subject must have histologically confirmed at last relapse aggressive B-cell NHL according to \The 2016 revision of the WHO classification of lymphoid neoplasms\ defined as:
If, based on surgeon’s assessment, the patient is recommended to undergo surgical staging for histologically confirmed endometrial cancer or if IB1 cervical cancer is deemed eligible for surgical treatment of disease
Histologically confirmed diagnosis of malignant primary brain tumor or known metastatic cancer with brain lesion presumed to be metastatic
Pathologically or cytologically confirmed diagnosis of metastatic (stage IV) RAS wildtype CRC
Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary and its respective variants)
History of histologically confirmed melanoma as assessed per medical record review
Have histologically or cytologically confirmed small bowel carcinoid tumor
Participants must have histologically confirmed intracranial meningioma, grade II-III, that has recurred or progressed after previous treatment
a primary brain tumor that has been histologically confirmed
Patients must have either \r\n* 1) histologically/cytologically-confirmed borderline resectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care, or \r\n* 2) histologically/cytologically-confirmed locally advanced unresectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care
Patients must have histologically-confirmed HNSCC with surgically resectable disease
Histologically or cytologically-confirmed advanced or metastatic GIST with a D842V mutation in the PDGFRA gene as determined by central laboratory testing
Age ? 18 years with histologically- or cytologically-confirmed, extensive-stage, chemotherapy-naïve SCLC
Participants must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes:
Histologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT) in subjects with relapsed or refractory disease who have failed standard therapy
